Sign up
Pharma Capital

Invivo Therapeutics jumps as third patient responds to spinal cord treatment

Inivivo has recruited five patients, three of which have been upgraded to a partial from complete injury after six months treatment.
Surgery.jpg
Spinal cord injuries have improved in 3 of 5 patients treated so far

Shares in InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV) soared as a third patient with severe spinal cord injuries responded well in a study.

So far, Inivivo has recruited five patients, three of which have been upgraded to a partial from complete injury after six months treatment.

Previous studies reported less than few than 16% paralysed by spinal injuries showed a notable improvement.

Mark Perrin, Invivo’s chief executive said, “We are encouraged to see this patient’s significant neurological progress.

Our goal is to approach full enrolment of the pivotal INSPIRE study by the end of the year, which will allow for an HDE (Humanitarian Device Exemption) submission in 2017.”

Invivo aims to recruit 20 patients for the INSPIRE study.

Shares rose 25% to US$9.42, valuing Invivo at US$290mln.

PhilW.jpg


Register here to be notified of future NVIV Company articles
View full NVIV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.